Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial

Lurbinectedin (Zepzelca®) is a novel anticancer agent that inhibits trans-activated transcription and modulates tumor microenvironment. In June 2020, FDA granted accelerated approval to lurbinectedin 3.2 mg/m2 q3wk for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy based on results of a phase II study (Lancet Oncol 2020 May;21(5):645-654). Lurbinectedin showed high activity in second-line SCLC patients treated with the lurbinectedin+doxorubicin combination (Ann Oncol 2017 Oct 1;28(10):2559-2566; Invest New Drugs 2021 Mar 11) consistent with the synergistic effects found in vitro/in vivo.